Key result
Bumetanide caused significant natriuresis and chloruresis acutely and was an effective long-term diuretic at doses up to 0.10 mg/kg daily in infants with heart failure, with no side effects.
Why the study?
Does bumetanide improve diuresis safely in infants with congenital heart disease and cardiac failure?
Observational (n=25)
Does bumetanide improve diuresis safely in infants with congenital heart disease and cardiac failure?
Bumetanide is an effective and safe diuretic for both acute and long-term management of cardiac failure in infants with congenital heart disease.
Should not yet change practice in infant HF; leaves open bumetanide's role pending controlled trials.
The effect of bumetanide in infants with congenital heart disease presenting with cardiac failure was studied. The study was divided into acute (3 days) and long-term (mean 10.5 weeks) cases. A total of 12 male infants was included in the acute study and 13 cases were evaluated in the long-term study. The dose used in the acute study (0.015 mg/kg) was suboptimal; notwithstanding it was found to cause significant natriuresis and chloruresis. Bumetanide in doses varying in different infants from as little as 0.015 mg/kg on alternate days to as much as 0.10 mg/kg daily was shown to be an effective diuretic for long-term use. No side effects were observed in either study.
No takes yet. Share an insight, caveat, or question.
Ward et al. (1977) conducted an observational in Congenital heart disease presenting with cardiac failure (n=25). Bumetanide was evaluated on Natriuresis, chloruresis, and diuretic efficacy. Bumetanide caused significant natriuresis and chloruresis acutely and was an effective long-term diuretic at doses up to 0.10 mg/kg daily in infants with heart failure, with no side effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: